Two Sigma Investments, LP Jounce Therapeutics, Inc. Transaction History

Two Sigma Investments, LP

$42.3 Billion
Q3 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$0.9 - $1.85 $21,945 - $45,110	24,384 Added 46.17%	77,200 $142,000
Q4 2022 Feb 14, 2023	SELL	$0.64 - $1.99 $28,261 - $87,874	-44,158 Reduced 45.54%	52,816 $58,000
Q3 2022 Nov 14, 2022	SELL	$2.73 - $4.92 $98,583 - $177,666	-36,111 Reduced 27.13%	96,974 $227,000
Q2 2022 Aug 15, 2022	BUY	$2.8 - $7.67 $190,251 - $521,153	67,947 Added 104.31%	133,085 $403,000
Q1 2022 May 16, 2022	SELL	$6.01 - $8.54 $1.52 Million - $2.16 Million	-253,413 Reduced 79.55%	65,138 $442,000
Q4 2021 Feb 14, 2022	BUY	$7.11 - $9.64 $680,057 - $922,046	95,648 Added 42.91%	318,551 $2.66 Million
Q3 2021 Nov 15, 2021	SELL	$5.04 - $8.73 $376,619 - $652,357	-74,726 Reduced 25.11%	222,903 $1.66 Million
Q2 2021 Aug 16, 2021	BUY	$6.58 - $10.66 $1.33 Million - $2.16 Million	202,780 Added 213.79%	297,629 $2.02 Million
Q1 2021 May 17, 2021	BUY	$6.73 - $13.87 $638,333 - $1.32 Million	94,849 New	94,849 $974,000
Q1 2020 May 15, 2020	SELL	$2.91 - $8.7 $360,604 - $1.08 Million	-123,919 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$2.81 - $9.21 $191,242 - $626,814	68,058 Added 121.83%	123,919 $1.08 Million
Q3 2019 Nov 14, 2019	SELL	$3.33 - $4.93 $130,779 - $193,615	-39,273 Reduced 41.28%	55,861 $186,000
Q2 2019 Aug 14, 2019	SELL	$4.3 - $6.73 $430,533 - $673,834	-100,124 Reduced 51.28%	95,134 $471,000
Q1 2019 May 15, 2019	SELL	$3.43 - $6.87 $708,891 - $1.42 Million	-206,674 Reduced 51.42%	195,258 $1.21 Million
Q4 2018 Feb 14, 2019	BUY	$2.69 - $6.71 $217,521 - $542,590	80,863 Added 25.19%	401,932 $1.36 Million
Q3 2018 Nov 14, 2018	BUY	$6.5 - $8.37 $765,960 - $986,320	117,840 Added 57.98%	321,069 $2.09 Million
Q2 2018 Aug 14, 2018	BUY	$7.27 - $21.88 $1.48 Million - $4.45 Million	203,229 New	203,229 $1.56 Million

Others Institutions Holding JNCE

# of Institutions

Shares Held

720K

Call Options Held

Put Options Held

View Full List

About Jounce Therapeutics, Inc.

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

More about JNCE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.

Account